Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT06379022 |
| Other study ID # |
AUTh-29/21-11-2018 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 3, 2018 |
| Est. completion date |
November 29, 2019 |
Study information
| Verified date |
April 2024 |
| Source |
Aristotle University Of Thessaloniki |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
In 10 systemically healthy non-smokers, free of periodontitis, one newly restored implant
(baseline-T0) and one corresponding tooth were followed over 12 months (T1). All implants
were screw-retained, and platform-switched. Oral hygiene was closely monitored during the
study. Probing pocket depth (PPD), attachment levels (CAL), bleeding and plaque indices and
crevicular fluid were collected from an implant-site (PICF) and a tooth-site (GCF). Total
proteomic profiles in PICF and GCF were investigated using label-free quantitative
proteomics.
Description:
Study population A total of 10 systemically healthy non-smokers, who were previously treated
for periodontal disease and received implant therapy, were recruited between December 2018
and November 2019. Each subject contributed with a newly restored screw-retained implant 2-4
weeks following functional loading (baseline, T0) and was closely followed over 12 months
(T1). All study implants were platform-switched (ø4.1. Straumann® Bone Level) and were
installed following a two-stage surgical placement protocol. A contralateral tooth in the
same jaw, but on the opposite quadrant, served as the control. Implant placement was planned
based on clinical and cone beam computerized tomography evaluations and was performed using a
prosthetic guide. Implants were submerged and were exposed 6 months later when a healing
abutment was adjusted on the fixture followed by a screw-retained crown 1 month later.
Exclusion criteria included younger than 18 years of age, <18 teeth (excluding third molars),
untreated periodontal disease, periodontitis Stage III-IV, evidence of peri-implantitis
(Berglundh et al, 2018) at other implant sites, significant soft tissue pathology, untreated
carious cavities (five or more), systemic diseases that require intake of medications,
medical conditions that contraindicated surgical implant placement, the medication that
interferes with bone metabolism, pregnancy or lactation, inadequate dimensions of the
alveolar ridge or grafted bone at the surgical site, and tooth extraction 3 months prior to
the study, smoking.
Clinical assessments Site-specific and full-mouth clinical indices were assessed at T0 and
T1. Oral hygiene instructions using a manual toothbrush and the modified Bass technique were
re-iterated at four time points over the 12-month study period (T0, 3-, 6-months and T1).
Prophylaxis comprising supragingival ultrasonic debridement and polishing with a rubber cup
was carried out at the same time points. In detail, the following site-specific clinical
indices probing pocket depth (PPD), clinical attachment levels (CAL), recession (REC),
modified gingival index (MGI) (score range 0-4) (Lobene et al. 1986), modified dental plaque
index (mPI)1 (score range: 0-3) and modified sulcus bleeding index (mBI)1 (score range: 0-3)
were determined at the mesial buccal site of the study implant in a similar manner as PPD,
CAL, REC, MGI, plaque index (PI)2 (score range: 0-3) and sulcus bleeding index (SBI)3 (score
range: 0-5) at the control tooth site. The width of keratinized tissues (KTW) was determined
at the mid-buccal aspect of the test-implant/control tooth. Moreover, on a full-mouth basis
PPD, CAL and dichotomous supragingival dental plaque (PI) (O'Leary et al., 1972) and bleeding
on probing (BOP) (Ainamo et al., 1975) were recorded at six sites per tooth/implant present
in the mouth. Periodontal clinical indices were determined using a manual periodontal probe
(PCP-UNC 15; Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) to the nearest millimeter.
Radiographic examination The VixWin™ Platinum Gendex software (Hatfield, PA, USA) linearly
assessed the distance between the implant platform and the bone crest (I-BC) parallel to the
long axis of the implant fixture at T0 and T1 on intra-oral digital radiographs. Periapical
digital radiographs (RadioVisioGraphy; Trophy Radiology S.A., Paris, France) were obtained
using the long cone paralleling technique at a 10 cm distance between the x-ray head and the
digital sensor.
Collection of crevicular fluid samples Peri-implant crevicular fluid (PICF) was collected
from the mesial-buccal site of the newly restored study implant, while gingival crevicular
fluid (GCF) was collected from the mesial-buccal site of a contralateral control tooth at T0
and T1. Before PICF/GCF collection, the surfaces were gently air-dried and isolated from
saliva by placing cotton rolls and using a saliva ejector. Then, supragingival plaque was
carefully removed by sterile curettes and paper strips (Periopaper, OraFlow Inc., Smithtown,
NY, USA) were gently placed in the mesial aspect of the peri-implant/gingival sulcus until
mild resistance was felt and held for 30 sec. Care was taken to avoid mechanical trauma when
placing the strips and those strips contaminated with blood were discarded. The strips were
stored in Eppendorf tubes (Eppendorf, Hamburg, Germany) at -80C until further processed.
Proteomic analysis of crevicular fluid samples (PICF/GCF) The PICF and GCF samples collected
from the study implant sites (n=10) and the control tooth sites (n=10), respectively at T0
and T1 were pooled and used for proteomics analysis. In brief, 20 µg of total protein per
pooled sample were reduced, alkylated, trypsinized, and purified with single-pot,
solid-phase-enhanced sample preparation (SP3) assisted protein digestion using the PreOmics'
SP3-iST (PreOmics GmbH) following the manufacturing protocol for protein extraction and
digestion. These extracts were concentrated using a Speedvac (Thermo Savant SPD121P, Thermo
Scientific, Waltham, MA, USA) and stored at -20 °C until further use.
The digested samples were first reconstituted with 30 µL of 3% acetonitrile (ACN) in 0.1%
formic acid then subjected to Fusion Orbitrap Lumos mass spectrometer (Thermo Fisher
Scientific) interfaced to an Easy nano-flow HPLC system (Thermo Fisher Scientific) for
proteomics analysis. During proteomics analysis, a three-liner gradient of acetonitrile and
water was used with 0.1% formic acid at a 300 nL/minute flow rate. The gradient progressed
from 2% to 30% acetonitrile over 60 minutes, then from 30% to 97% acetonitrile in 10 minutes,
and finally held at 97% acetonitrile for 10 minutes. The mass spectrometer was set to operate
in a data-dependent manner, automatically switching between MS and MS/MS using the Xcalibur
software package from Thermo Fisher Scientific. A mass range of 300-1500 m/z was selected for
the Orbitrap analyzer.
The acquired MS data were processed using the Mascot (version 2.4.1, Matrix Science) search
engine against an in-house database containing 10,125,458 entries, which included human
(accessed on 22nd February 2022 from Uniprot) and bacterial (accessed on 22nd February 2022
from eHOMD) proteins, common MS contaminants, and reverse sequences for estimating the false
discovery rate. During the proteomics analysis, the precursor ion tolerance and fragment ion
tolerance were set to 10 ppm and ±0.6 Da, respectively. Up to two missed cleavages per
peptide were allowed for tryptic digestion. The carbamidomethylation modification on cysteine
was selected as a fixed modification, while deamidation of asparagine and glutamine and
oxidation of methionine were chosen as variable modification parameters.
The spectrum reports of the search results were generated using Scaffold software (version
4.2.1, Proteome software), and proteins with FDR at 1%, minimal 2 unique peptides identified,
as peptide FDR at 0.1% were used for relative protein abundance analysis. Fold changes in
abundance intensity were calculated based on value log2 fold change (FC) between pairs of
consecutive time points using R-software (R: A Language and Environment for Statistical
Computing, R Development Core Team). Proteins with a log2FC ≥ 1 of unique spectrum counts
between two conditions or exclusively identified in one condition were considered regulated.
Bioinformatics analysis for the regulated proteins The regulated proteins underwent
overrepresentation analysis (ORA) against the Hallmark database using the WebGestalt online
tool. The analysis, conducted on March 25th, 2022, aimed to compare the regulation of
proteins in teeth and implants between T0 and T1 conditions. Similarly, on March 29th, 2022,
the analysis examined the regulation of proteins in both teeth and implants under either the
T0 or T1 conditions. The top 10 enriched results, ranked by p-value using the hypergeometric
distribution, were reported. However, only pathways with a p-value < 0.05 were considered as
regulated.
